Exosome Diagnostics Reports Major Technical Advance; Company’s Novel Spin Column Method Offers Standardized, Reliable Method to Isolate Exosomal RNA, Enabling Suitability for Routine Laboratory Use

On September 3, 2015, Exosome Diagnostics, Inc., a Cambridge, Massachusetts-based developer of revolutionary, biofluid-based molecular diagnostics, announced the publication of new data demonstrating the ability of its proprietary, exosome-based technology to isolate and extract highly pure RNA from serum and plasma samples for use in research laboratories. The data, published on August 28, 2015 in PLOS ONE, an international, peer-reviewed, open-access online journal, showed that the Exosome Diagnostics technology platform yielded high-quality exosomal RNA (exoRNA) of equal or higher quantity in a faster timeframe and with more consistent results compared to traditional ultracentrifugation methods, which are labor-intensive and subject to significant variability. The article is titled: “Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method.” “With the explosive rise in targeted cancer therapy development, exosomes are increasingly utilized as an important source of deriving key molecules for biomarker and companion diagnostics development. Extraction and isolation are the first critical step,” said Johan Skog, Ph.D., Chief Scientific Officer, Exosome Diagnostics. “We are very pleased with these new data as they demonstrate the clear advantages of our novel spin column method versus traditional exosomal RNA extraction methods. Using our technology, researchers can maximize the full potential of this incredibly rich source of nucleic acids to explore and deliver cutting-edge scientific advancements.” A key source of nucleic acids, including RNA, exosomes are vesicular messengers secreted by all living cells and carried throughout the body via biofluids, such as plasma, urine, and cerebrospinal fluid.
Login Or Register To Read Full Story